➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Johnson and Johnson
AstraZeneca
Moodys
Dow

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Patent: 10,322,104

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,322,104
Title:Disulfur bridge linkers for conjugation of a cell-binding molecule
Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
Inventor(s): Zhao; Robert Yongxin (Lexington, MA)
Assignee: HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)
Application Number:15/479,859
Patent Claims:see list of patent claims

Details for Patent 10,322,104

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Merck
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.